Login to Your Account

BIO Investor Forum

Panel: Focus on IP, Not Cash When Inking Multi-Asset Deals

By Jennifer Boggs
Managing Editor

Thursday, October 27, 2011

SAN FRANCISCO – The final day of the 2011 BIO Investor Forum started with some encouraging news: The discovery-stage deal is alive and well for biotech.

In the last two months alone, BioWorld Today has reported on several deals, including Ipsen SA's multi-asset deal with Syntaxin Ltd. for botulinum toxin drugs; Merck Serono SA's potential $691 million inflammatory disease antibody collaboration with F-Star GmbH; and Merck & Co. Inc. becoming the first major commercialization partner in an early stage deal for Zymeworks Inc.'s bi-specific antibody technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription